Therapeutic Drug Monitoring of Second- and Third-Generation Antipsychotic Drugs-Influence of Smoking Behavior and Inflammation on Pharmacokinetics
| Autor: | Gabriel Eckermann, Hannah Benedictine Maier, Gudrun Hefner, Sermin Toto, Renate Grohmann, Catharina Meissner, Johanna Seifert, Johannes Heck, Stefan Bleich, Nicole Moschny, Flverly Francis |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Drug
Olanzapine medicine.medical_specialty medicine.medical_treatment media_common.quotation_subject therapeutic drug monitoring Pharmaceutical Science Context (language use) Review smoking behavior 03 medical and health sciences 0302 clinical medicine Pharmacy and materia medica intoxication Drug Discovery medicine Antipsychotic Intensive care medicine Clozapine media_common AGNP consensus guidelines medicine.diagnostic_test clozapine business.industry reference ranges 030227 psychiatry Neuropsychopharmacology RS1-441 CYP enzyme induction/de-induction Therapeutic drug monitoring inflammation second- and third-generation antipsychotic drugs Molecular Medicine Medicine business pharmacokinetics 030217 neurology & neurosurgery Pharmacogenetics medicine.drug |
| Zdroj: | Pharmaceuticals Pharmaceuticals, Vol 14, Iss 514, p 514 (2021) |
| ISSN: | 1424-8247 |
| Popis: | Both inflammation and smoking can influence a drug’s pharmacokinetic properties, i.e., its liberation, absorption, distribution, metabolism, and elimination. Depending on, e.g., pharmacogenetics, these changes may alter treatment response or cause serious adverse drug reactions and are thus of clinical relevance. Antipsychotic drugs, used in the treatment of psychosis and schizophrenia, should be closely monitored due to multiple factors (e.g., the narrow therapeutic window of certain psychotropic drugs, the chronicity of most mental illnesses, and the common occurrence of polypharmacotherapy in psychiatry). Therapeutic drug monitoring (TDM) aids with drug titration by enabling the quantification of patients’ drug levels. Recommendations on the use of TDM during treatment with psychotropic drugs are presented in the Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology; however, data on antipsychotic drug levels during inflammation or after changes in smoking behavior—both clinically relevant in psychiatry—that can aid clinical decision making are sparse. The following narrative review provides an overview of relevant literature regarding TDM in psychiatry, particularly in the context of second- and third-generation antipsychotic drugs, inflammation, and smoking behavior. It aims to spread awareness regarding TDM (most pronouncedly of clozapine and olanzapine) as a tool to optimize drug safety and provide patient-tailored treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|